REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal

BACKGROUND: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal. METHODS: Retrospective...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurol Sci
Autors principals: Batista, S., Nunes, C. C., Cerqueira, J. J., Martins Silva, Ana, Correia de Sá, J., Ferreira, J., Mendonça, M. T., Pinheiro, J., Salgado, V., Correia, A. S., Sequeira, J., Costa, A., Sousa, L.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043899/
https://ncbi.nlm.nih.gov/pubmed/32997282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10072-020-04726-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars